Mudit Jain, MD
Internal Medicine · Plantation, FLNPI 1356305601
Payments from drug & device makers
Across 375 payments — averaging $1025.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$355K
- Corcept Therapeutics$21K
- Medtronic$1K
- Novo Nordisk$1K
- Lilly USA, LLC$881
- Sanofi-aventis U.S. LLC$827
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$17,83060%
- Travel & lodging$2,7469%
- Food & beverage$9,05130%
- Education$1821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $355,201 |
| Corcept Therapeutics | 46 | $20,860 |
| Medtronic(2 entities) | 14 | $1,270 |
| Novo Nordisk | 48 | $1,163 |
| Lilly USA, LLC | 39 | $881 |
| Sanofi-aventis U.S. LLC | 42 | $827 |
| AstraZeneca(2 entities) | 21 | $499 |
| Amgen(2 entities) | 13 | $471 |
| Tandem Diabetes Care, Inc. | 2 | $409 |
| Boehringer Ingelheim | 17 | $400 |
| Bayer | 11 | $325 |
| Dexcom, Inc. | 12 | $320 |
| Mannkind Corporation | 11 | $309 |
| Insulet Corporation | 14 | $281 |
| Johnson & Johnson | 6 | $272 |
| Abbott | 3 | $172 |
| Amarin Pharma, Inc. | 8 | $148 |
| Ascendis Pharma Endocrinology Inc | 4 | $147 |
| Novartis | 5 | $125 |
| CSL Behring | 1 | $102 |
| Xeris Pharmaceuticals, Inc. | 5 | $94 |
| Amneal Pharmaceuticals LLC | 4 | $84 |
| Merck | 4 | $74 |
| BETA Bionics, Inc. | 2 | $51 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Lifescan, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| EUSA Pharma (US) LLC | 1 | $24 |
| Roche Diabetes Care, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Cequr Corporation | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$19,533
- MINIMED 780G$967
- t-slim insulin pump$300
- Repatha$241
- FREESTYLE LIBRE 3$135
- Kerendia$125
- MOUNJARO$125
- INVOKANA$111
- t:slim X2 insulin pump$109
- Ozempic$109
- XARELTO$106
- Hizentra$102
- DEXCOM CGM$102
How this compares
$384,730 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 701 | $854,817 |
| KorlymMifepristone | 24 | $559,198 |
| JardianceEmpagliflozin | 383 | $344,037 |
| MounjaroTirzepatide | 223 | $294,107 |
| FarxigaDapagliflozin Propanediol | 267 | $262,757 |
| TrulicityDulaglutide | 171 | $219,792 |
| Tresiba Flextouch U-200Insulin Degludec | 143 | $129,996 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 87 | $103,721 |
| TradjentaLinagliptin | 134 | $98,724 |
| Humalog Kwikpen U-200Insulin Lispro | 62 | $69,359 |
| Novolog FlexpenInsulin Aspart | 250 | $57,742 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 47 | $57,215 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 478 | $53,109 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $48,465 |
| JanuviaSitagliptin Phosphate | 57 | $46,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $1,163 | $925,611845 claims |
| Corcept TherapeuticsKorlym | $20,860 | $559,19824 claims |
| Lilly USA, LLCMounjaro, Trulicity | $881 | $513,899394 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr | $400 | $495,967567 claims |
| AstraZenecaFarxiga | $499 | $262,757267 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $827 | $112,335128 claims |
| MerckJanuvia, Janumet | $74 | $78,16887 claims |
| AbbVieSynthroid | $355,201 | $24,503291 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $84 | $14,075909 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Plantation
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.